Microbes – Experts

Microbes: Invisible Invaders … Amazing Allies MICROBES EXPERTS

The following experts are available for media interviews in conjunction with the “Microbes: Invisible Invaders … Amazing Allies” exhibit. Interested media should contact Meghan Marschall at 212/733-4753 to arrange an interview (except where otherwise noted).

ANTI-INFECTIVE RESEARCH & MEDICAL PRACTITIONERS

VINCENT T. ANDRIOLE, M.D.
Professor of Medicine, Yale University of Medicine
Attending Physician, Yale-New Haven Hospital

Dr. Vincent T. Andriole received the B.S. degree from the College of the Holy Cross and his M.D. from Yale University School of Medicine. He completed his postgraduate training at North Carolina Memorial Hospital, National Institutes of Allergy and Infectious Diseases/National Institutes of Health, and Yale University School of Medicine. Dr. Andriole is also a member of numerous professional societies, including the American Federation for Clinical Research, American Society of Clinical Investigation, New York Academy of Sciences, American College of Physicians, and the American Association for the Advancement of Science. In addition, he is a past president of the Infectious Diseases Society of America.

Dr. Andriole is currently a member of the editorial boards of the “Journal of Antimicrobial Chemotherapy,” “Diagnostic Microbiology” and “Infectious Disease,” an editor of the “Mediguide to Infectious Diseases,” “Current Opinion in Infectious Diseases” and “Cliniguide to Fungal Infections.” He is also a peer reviewer for numerous journals including the “New England Journal of Medicine,” “American Journal of Medicine,” “Annals of Internal Medicine,” “Journal of Infectious Diseases,” “Reviews of Infectious Diseases/Clinical Infectious Diseases,” and “Antimicrobial Agents and Chemotherapy.”

STEVEN BRICKNER, Ph.D.
Manager of Medicinal Chemistry, Pfizer Central Research

Dr. Steven Brickner has first-hand experience with the discovery approaches the pharmaceutical industry is pursuing to develop new drugs to meet the growing resistance problem and is highly knowledgeable about issues of bacterial multi-drug resistance. His career has been focused entirely on the discovery and development of novel antibacterial agents. Prior to joining Pfizer, he led a team which developed two clinical candidates of a new class of antibacterial agents, the oxazolidinones, one of which is currently in Phase III human efficacy trials. The oxazolidinones have proven extremely active in animals infected with multi-drug resistant Gram-positive pathogens, and Dr. Brickner is a recognized world expert on them.

Dr. Brickner received the B.S. degree with honors from Miami University of Ohio, his M.S. organic chemistry from Cornell University and his Ph.D. organic chemistry from Cornell University.

STEVEN C. GILMAN, Ph.D.
Assistant Director, Immunology and Infectious Disease, Pfizer Central Research

Dr. Steven Gilman is responsible for drug discovery programs aimed at developing novel therapeutics for the treatment of hospital and community acquired infections, organ transplant rejection, autoimmunity and immunodeficiency diseases. Prior to joining Pfizer, Dr. Gilman held a number of scientific and management positions in the pharmaceutical and biotechnology industry. From 1991-1994 he was a research director at Sterling Winthrop Pharmaceuticals, responsible for Inflammatory Diseases and Oncology discovery programs. Prior to this, Dr. Gilman held the position of director of biology at Cytogen Corporation, where he was responsible for the discovery and preclinical development of therapeutic and imaging monoclonal antibody programs. Dr. Gilman’s pharmaceutical career began at Wyeth Laboratories as a senior scientist and manager, immunoinflammatory pharmacology.

Dr. Gilman received the B.A. degree in microbiology and chemistry from Miami University of Ohio in 1975 and his M.S. (1977) and Ph.D. (1979) from the Pennsylvania State University.

SCOTT HOPKINS, M.D.
Group Director, Clinical Research, Pfizer Central Research

Dr. Scott Hopkins has worked in the pharmaceutical industry for more than 10 years and has been involved in the development of some of the most commonly used antibacterial, antifungal, and antimalarial agents in use. He has published reports in a number of medical journals, including the “New England Journal of Medicine” and the “American Journal of Medicine.”

Dr. Hopkins received his undergraduate degree at Princeton University in Biochemistry and his medical degree at the University of Virginia. He received further training in internal medicine and infectious diseases at Georgetown University and the Medical University of South Carolina and is board certified in both specialties.

RANDALL KAYE, M.D.
Pediatric Health, Director, Team Leader, Pfizer Pharmaceuticals Group

In his role as director of pediatric health at Pfizer, Dr. Kaye oversees programs such as Bright Futures, a partnership with the Maternal Child Health Bureau, a division of the U.S. Department of Health and Human Services, advocating contextual pediatrics. Since November 1993, Dr. Kaye has been a volunteer on The Floating Hospital, a four-deck ship docked at Pier 11 on the East River of Manhattan that provides health care services for the medically under-served, including inner-city children and those from low-income families.

Dr. Kaye earned his bachelor’s degree in Science, his master’s in public health and his doctor of medicine from The George Washington University. Dr. Kaye completed his pediatric residency in a community-based pediatric program at the University of Massachusetts Medical Center. He completed his research fellowship in allergy and immunology at Harvard Medical School. Dr. Kaye is a member of the American Academy of Pediatrics, the American Academy of Allergy, Asthma and Immunology, the American Medical Association, and the New York State Medical Society.

MIKE MAGEE, M.D.
Senior Medical Advisor, Pfizer Inc
Professor of Surgery, Jefferson Medical College

Dr. Mike Magee is called upon to speak worldwide for Pfizer and for the pharmaceutical industry on a wide range of clinical and public policy issues that impact the quality of life. Dr. Magee has consulted for the United States Congress, the American Medical Association, the American Association of Medical Colleges, and the American Hospital Association. Dr. Magee is past president of the National Association of Physician Broadcasters and a former radio and television columnist.
Dr. Magee attended medical school in Syracuse, N.Y., and did his surgical residency at the University of North Carolina. In addition to 13 years as a physician in New England, Dr. Magee served as senior vice president of Pennsylvania Hospital in Philadelphia.

ALAN R. PROCTOR, Ph.D.
Executive Director, Department of Cancer, Immunology and Infectious Diseases
Pfizer Central Research

In his current role, Dr. Alan Proctor is responsible for research programs that seek to understand the causes of human diseases and to discover new medicines for treating a wide range of illnesses. These programs include identifying novel antibacterial agents, particularly those effective against emerging strains of pathogens that are resistant to multiple classes of antibacterial agents, and identifying agents that modulate effects of the immunological system. Dr. Proctor led the development of recombinant DNA-molecular biological technologies at Pfizer before assuming his current role four years ago.

Dr. Proctor holds an A.B. degree from the University of North Carolina at Chapel Hill, and M.S. and Ph.D. degrees from North Carolina State University, Raleigh, N.C.

W. MICHAEL SCHELD, M.D.
Professor of Internal Medicine and Neurosurgery, University of Virginia
Associate Chair for Residency Programs, University of Virginia

Dr. Michael Scheld attended Cornell University for his undergraduate degree and he received his M.D. from Cornell University Medical College. Dr. Scheld was resident in the Department of Internal Medicine at the University of Virginia, followed by a fellowship in Infectious Diseases at the same institution. The National Institute of Allergy and Infectious Diseases has supported his research on pathogenesis and pathophysiology of bacterial meningitis. Dr. Scheld is a fellow of the Infectious Diseases Society of America. He served as chair of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Program Committee from 1995 through 1997.

Dr. Scheld is the author or co-author of more than 300 original scientific articles, review articles and book chapters. He is also co-editor of the definitive textbook entitled “Infections of the Central Nervous System” with Drs. Durack and Whitley.

DOUG WEBB, Ph.D.
Director, Anti-Infectives, Pfizer Inc

Dr. Doug Webb coordinates research and development and marketing support for Pfizer anti-infectives. He has coordinated R&D activities for new product development and has conducted clinical activities for anti-infectives and calcium channel blockers. Prior to his work at Pfizer, Dr. Webb was director of scientific relations at Miles Pharmaceuticals and before that he was the assistant director, licensing and development, for the Centers for Disease Control and Prevention.
Dr. Webb earned his bachelor of arts degree from Emory University and his master’s in bacteriology and his Ph.D. in microbiology from the University of Georgia.

LOWELL S. YOUNG, M.D.
Director, Kuzell Institute for Arthritis and Infectious Diseases
Chief of the Division of Infectious Diseases, California Pacific Medical Center
Clinical Professor of Medicine, University of California, San Francisco

Dr. Lowell Young is a board-certified specialist in internal medicine with a subspecialty in infectious diseases. Dr. Young received his medical degree from Harvard Medical School in Boston, Mass., and completed an internship at Cornell Medical Division, a junior assistant residency at Bellevue Hospital, and a senior assistant residency at Memorial Hospital, all in New York City. Dr. Young was also a postdoctoral fellow of the National Institute of Allergy and Infectious Diseases.

A fellow of the American College of Physicians and the Infectious Diseases Society of America, Dr. Young has written or contributed to more than 60 books and book chapters and more than 200 papers on empiric therapy. He is a member of the American Society for Microbiology. Dr. Young currently serves as a member of the Advisory Council, NIAID, and editor, “Antimicrobial Agents and Chemotherapy.”

NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

Any reporters interested in speaking to a NIH expert should call the NIAID press office at 301-402-1663.

EXHIBIT PRODUCERS
MARK GREENBERG
President and Chief Executive Officer of Evergreen Exhibitions

Founded in late 1992, Evergreen Exhibitions is the largest private enterprise collaborating with the nonprofit museum community to provide comprehensive development, production and tour maintenance services for traveling exhibits worldwide. To arrange an interview with Mr. Greenberg, contact Mike Kempf at 210-599-0045.

For additional information on this Microbes article, please contact:

Mike Kempf
(210) 599-0045
Mike@evergreenexhibitions.com

Source: Evergreen Exhibitions
http://www.mikekempf.wpengine.com